Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1817-1819

  Doubek, Michael ^a,b   Trbušek, Martin ^a,b   Malčíková, Jitka ^a,b   Brychtová, Yvona ^a   Šmardová, Jana ^c   Lochmanová, Jana ^a   Panovská, Anna ^a   Francová, Hana Skuhrová ^a   Mráz, Marek ^a,b   Tichý, Boris ^a,b   Šebejová, Ludmila ^a,b   Navrkalová, Veronika ^a,b   Plevová, Karla ^a   Kuglík, Petr ^d   Mayer, Jiří ^a,b   Pospíšilová, Šárka ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b CENTRAL EUROPEAN INSTITUTE OF TECHNOLOGY   (Czech Republic)

^c Department of Pathology   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; COTRIMOXAZOLE; PROTEIN P53;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DNA BINDING MOTIF; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LETTER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864966422     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.658794     Document Type: Letter

References (9)

1. M alcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: Selection, impact on survival, and response to DNA damage. Blood 2009;114:5307-5314.
2. T rbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703-2708.
3. E ichhorst B, Hallek M, Dreyling M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl. 4):102-104.
4. H allek M, Cheson BD, Catovsky D, et al.; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111:5446-5456.
5. Osterborg A, Fo á R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;23:1980-1988.
6. D ö hner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343: 1910-1916.
7. Fiegl M, Erdel M, Tinhofer I, et al. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: A retrospective study on various cytogenetic risk categories. Ann Oncol 2010;21:2410-2419.
8. F iegl M, Falkner F, Steurer M, et al. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: Multicenter survey in 30 patients. Ann Hematol 2011;90:1083-1091.
9. Keating MJ, Flinn I, Jain V, et al. Th erapeutic role of alemtuzumab (Campath-1H) in patients who have failed fl udarabine: Results of large international study. Blood 2002;99:3554-3556.